Progress and challenges in diagnosis of dysferlinopathy

被引:67
作者
Fanin, Marina [1 ]
Angelini, Corrado [2 ]
机构
[1] Univ Padua, Dept Neurosci, Biomed Campus Pietro dAbano,Via Giuseppe Orus 2B, I-35129 Padua, Italy
[2] Fdn San Camillo Hosp IRCCS, Venice, Italy
关键词
dysferlin; dysferlinopathy; LGMD2B; Miyoshi myopathy; mutation detection; NGS; protein testing; GIRDLE MUSCULAR-DYSTROPHY; CARDIOVASCULAR MAGNETIC-RESONANCE; ANTERIOR COMPARTMENT MYOPATHY; DEFECTIVE MEMBRANE REPAIR; LIMB-GIRDLE; MIYOSHI MYOPATHY; SKELETAL-MUSCLE; LATE-ONSET; DISTAL MYOPATHY; KOREAN PATIENTS;
D O I
10.1002/mus.25367
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Dysferlin-deficient limb girdle muscular dystrophy type 2B, distal Miyoshi myopathy, and other less frequent phenotypes are a group of recessive disorders called dysferlinopathies. They are characterized by wide clinical heterogeneity. To diagnose dysferlinopathy, a clinical neuromuscular workup, including electrophysiological and muscle imaging investigations, is essential to support subsequent laboratory testing. Increased serum creatine kinase levels, distal or proximal muscle weakness, and myalgia with onset in the second or third decades are the main clinical features of the disease. In muscle biopsies, severe dysferlin deficiency by immunoblot or its abnormal localization by immunohistochemistry are the gold standard, as they have a high diagnostic value. Dysferlin testing on monocytes is a valuable alternative to muscle immunoblotting. Molecular techniques for gene mutation detection, such as next generation sequencing, have improved the genetic diagnosis, which is crucial for treatment and genetic counselling. Muscle Nerve54: 821-835, 2016
引用
收藏
页码:821 / 835
页数:15
相关论文
共 168 条
  • [1] Dysferlin-Deficient Muscular Dystrophy Identified Through Laboratory Testing for Elevated Aminotransferases
    Aasen, Tyler
    Achdjian, Houry
    Usta, Yousef
    Nanda, Rakesh
    [J]. ACG CASE REPORTS JOURNAL, 2016, 3 (02): : 127 - 129
  • [2] Amato Anthony A, 2011, Handb Clin Neurol, V101, P111, DOI 10.1016/B978-0-08-045031-5.00007-4
  • [3] Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies)
    Anderson, LVB
    Harrison, RM
    Pogue, R
    Vafiadaki, E
    Pollitt, C
    Davison, K
    Moss, JA
    Keers, S
    Pyle, A
    Shaw, PJ
    Mahjneh, I
    Argov, Z
    Greenberg, CR
    Wrogemann, K
    Bertorini, T
    Goebel, HH
    Beckmann, JS
    Bashir, R
    Bushby, KMD
    [J]. NEUROMUSCULAR DISORDERS, 2000, 10 (08) : 553 - 559
  • [4] Dysferlin is a plasma membrane protein and is expressed early in human development
    Anderson, LVB
    Davison, K
    Moss, JA
    Young, C
    Cullen, MJ
    Walsh, J
    Johnson, MA
    Bashir, R
    Britton, S
    Keers, S
    Argov, Z
    Mahjneh, I
    Fougerousse, F
    Beckmann, JS
    Bushby, KMD
    [J]. HUMAN MOLECULAR GENETICS, 1999, 8 (05) : 855 - 861
  • [5] Multiplex Western blotting system for the analysis of muscular dystrophy proteins
    Anderson, LVB
    Davison, K
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (04) : 1017 - 1022
  • [6] Andoni UJ, 2008, NEUROL INDIA, V56, P289
  • [7] Angelini C, 2011, Acta Myol, V30, P127
  • [8] The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B)
    Angelini, C.
    Nardetto, L.
    Borsato, C.
    Padoan, R.
    Fanin, M.
    Nascimbeni, A. C.
    Tasca, E.
    [J]. NEUROLOGICAL RESEARCH, 2010, 32 (01) : 41 - 46
  • [9] Angelini C, 1999, ACTA MYOL, V3, P61
  • [10] Angelini Corrado, 2011, Acta Myol, V30, P185